相关临床试验
0
0 进行中
药物批准
8
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
<p><strong>INDICATIONS</strong><br> NESP® is indicated for the treatment of anaemia associated with chronic renal failure (CRF).<br> NESP® is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.</p> <p>NESP® is also indicated for anaemia with myelodysplastic syndrome. The efficacy and safety of NESP® have not been established in patients who are in the intermediate-2 or high risk categories under the International Prognostic Scoring System (IPSS). Patients indicated for NESP® should be selected based on a full knowledge of the description in the “CLINICAL TRIAL” section – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>, including serum erythropoietin concentration in patients enrolled in clinical studies, as well as adequate understanding of the efficacy and safety of NESP® and reference to the academic guidelines and other relevant updates.</p>
<p><strong>INDICATIONS</strong><br> NESP® is indicated for the treatment of anaemia associated with chronic renal failure (CRF).<br> NESP® is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.</p> <p>NESP® is also indicated for anaemia with myelodysplastic syndrome. The efficacy and safety of NESP® have not been established in patients who are in the intermediate-2 or high risk categories under the International Prognostic Scoring System (IPSS). Patients indicated for NESP® should be selected based on a full knowledge of the description in the “CLINICAL TRIAL” section – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>, including serum erythropoietin concentration in patients enrolled in clinical studies, as well as adequate understanding of the efficacy and safety of NESP® and reference to the academic guidelines and other relevant updates.</p>
<p><strong>INDICATIONS</strong><br> NESP® is indicated for the treatment of anaemia associated with chronic renal failure (CRF).<br> NESP® is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.</p> <p>NESP® is also indicated for anaemia with myelodysplastic syndrome. The efficacy and safety of NESP® have not been established in patients who are in the intermediate-2 or high risk categories under the International Prognostic Scoring System (IPSS). Patients indicated for NESP® should be selected based on a full knowledge of the description in the “CLINICAL TRIAL” section – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>, including serum erythropoietin concentration in patients enrolled in clinical studies, as well as adequate understanding of the efficacy and safety of NESP® and reference to the academic guidelines and other relevant updates.</p>
<p><strong>INDICATIONS</strong><br> NESP® is indicated for the treatment of anaemia associated with chronic renal failure (CRF).<br> NESP® is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.</p> <p>NESP® is also indicated for anaemia with myelodysplastic syndrome. The efficacy and safety of NESP® have not been established in patients who are in the intermediate-2 or high risk categories under the International Prognostic Scoring System (IPSS). Patients indicated for NESP® should be selected based on a full knowledge of the description in the “CLINICAL TRIAL” section – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>, including serum erythropoietin concentration in patients enrolled in clinical studies, as well as adequate understanding of the efficacy and safety of NESP® and reference to the academic guidelines and other relevant updates.</p>
<p><strong>INDICATIONS</strong><br> NESP® is indicated for the treatment of anaemia associated with chronic renal failure (CRF).<br> NESP® is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.</p> <p>NESP® is also indicated for anaemia with myelodysplastic syndrome. The efficacy and safety of NESP® have not been established in patients who are in the intermediate-2 or high risk categories under the International Prognostic Scoring System (IPSS). Patients indicated for NESP® should be selected based on a full knowledge of the description in the “CLINICAL TRIAL” section – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>, including serum erythropoietin concentration in patients enrolled in clinical studies, as well as adequate understanding of the efficacy and safety of NESP® and reference to the academic guidelines and other relevant updates.</p>
<p><strong>4.1 Therapeutic indications</strong></p> <p><em><u>Chronic immune (idiopathic) thrombocytopenic purpura (ITP)</u></em></p> <p>Romiplate® is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p><em><u>Aplastic anaemia</u></em></p> <p>Romiplate® is indicated for adults with moderate to severe aplastic anaemia refractory to conventional therapies.</p>
<p><strong>INDICATIONS</strong><br> Secondary hyperparathyroidism in patients undergoing maintenance dialysis.</p>
**\[INDICATIONS\]** Acute leukemia (including blastic crisis in chronic leukemia), malignant lymphoma.
暂无资讯文章
